A Secret Weapon For Nemifitide diTFA
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo goals were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis patie